Clinical trials · Chicago, IL
Cancer clinical trials in Chicago
We’re tracking 620 recruiting cancer studies with a site in or near Chicago — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT00005095Recruiting
Ovarian cancer risk study: specimens and health data
This study collects tissue samples and medical information from people at higher risk for ovarian cancer or undergoing gynecologic surgery. Researchers use this data to develop better ways to detect and prevent ovarian cancer early.
Chicago, IllinoisAges 18–80 - NCT07838519Enrolling by invitation
Personalized lung cancer screening for veterans
This study tests a personalized approach to help veterans decide if lung cancer screening is right for them. It aims to improve early detection by considering each person's unique risk factors, such as smoking history, military exposures, and lung health.
Chicago, IllinoisAges 50–80 - NCT04620187RecruitingPhase 2
Study medicine T-DM1 after surgery for HER2-positive salivary cancer
This Phase 2 trial studies T-DM1 given after surgery for salivary gland cancer that is HER2-positive. The goal is to reduce the risk of the cancer coming back by targeting HER2-positive tumor cells.
Chicago, IllinoisAges 18 years+ - NCT05646316RecruitingPhase 3
Sentinel lymph node mapping to reduce leg swelling after surgery
This study tests whether a special way of finding lymph nodes during hysterectomy can lower the risk of long-term leg swelling or related dysfunction in people with stage I endometrial cancer. It compares standard lymph node assessment with sentinel lymph node mapping and looks at how this affects day-to-day leg functioning.
Chicago, IllinoisAges 18 years+ - NCT06144229Enrolling by invitation
HPV Vaccine in Women with HIV
This study looks at how well the HPV vaccine works in women living with HIV and whether it helps make cervical cancer screening more accurate. If you are a woman with HIV between 21 and 40 years old and already part of certain other HIV studies, you may be able to join.
Chicago, IllinoisAges 21–40 - NCT04267848RecruitingPhase 3
Testing immunotherapy with chemo after lung cancer surgery
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Chicago, IllinoisAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Chicago, IllinoisAges 18 years+ - NCT06498635RecruitingPhase 3
Immunotherapy after surgery for lung cancer with no remaining cancer
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
Chicago, IllinoisAges 18 years+ - NCT07595874RecruitingPhase 2
New Immunotherapy Drugs Before Surgery for Advanced Colorectal Cancer
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to treat advanced colorectal cancer that can be removed. The goal is to help the immune system fight cancer cells and improve outcomes after surgery.
Chicago, IllinoisAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Chicago, IllinoisAges 18 years+ - NCT07644559RecruitingPhase 2
Study of VS-7375 with cetuximab for advanced pancreatic cancer
This trial tests a new drug combination for people with a specific KRAS mutation in pancreatic cancer. It aims to see if the treatment can shrink tumors or slow the disease.
Chicago, IllinoisAges 18 years+ - NCT07217704RecruitingPhase 3
New PET scan to find stomach or esophageal cancer spread
This trial tests a new PET scan drug (18F-FAPI) to see if it can better detect where stomach or esophageal cancer has spread. It may help doctors plan the right treatment for you.
Chicago, IllinoisAges 18 years+ - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Chicago, IllinoisAges 18 years+ - NCT07446322RecruitingPhase 2
Study of a new drug plus standard chemo for advanced colorectal cancer
This trial tests if adding the experimental drug pelareorep to standard chemotherapy (FOLFIRI) and bevacizumab can help people with a specific type of advanced colorectal cancer that has a RAS mutation and is not caused by high microsatellite instability. You may be able to join if you've already tried one type of chemotherapy and it stopped working or you couldn't tolerate it.
Chicago, IllinoisAges 18 years+ - NCT07061977RecruitingPhase 3
New cancer drug combo for advanced cervical cancer
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Chicago, IllinoisAges 18 years+ - NCT07659782RecruitingPhase 2
Study of VS-7375 for KRAS G12D lung cancer
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
Chicago, IllinoisAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Chicago, IllinoisAges 18 years+ - NCT07817147Recruiting
Microwave ablation treatment for advanced cancer
This study tests a procedure called microwave ablation (using heat to destroy cancer cells) for tumors that are hard to remove with surgery. It aims to see if the procedure is safe and effective when done through a scope in the stomach.
Chicago, IllinoisAges 18 years+ - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Chicago, IllinoisAges 18 years+ - NCT07475806RecruitingPhase 2
Bladder-sparing drug combo for muscle-invasive bladder cancer
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
Chicago, IllinoisAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Chicago, IllinoisAges 18 years+ - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
Chicago, IllinoisAges 18 years+ - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Chicago, IllinoisAges 18 years+ - NCT05432804RecruitingPhase 1/Phase 2
Selinexor added to temozolomide for recurring brain glioblastoma
This trial studies whether adding selinexor to the standard chemotherapy temozolomide (with radiation) can better treat glioblastoma that has come back after prior treatment. If you meet specific tumor, health, and lab requirements, the goal is to slow tumor growth or improve symptoms.
Chicago, IllinoisAges 18 years+
Hear when a new Cancer trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting cancer studies listed above.
- Northwestern University · 9 studies
- Loyola University Medical Center · 5 studies
- Northwestern Medicine Cancer Center Warrenville · 5 studies
- University of Chicago Comprehensive Cancer Center · 5 studies
- University of Chicago Medicine-Orland Park · 5 studies
- University of Illinois · 5 studies
- Northwestern Medicine Cancer Center Delnor · 4 studies
- Northwestern Medicine Lake Forest Hospital · 4 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in Illinois.
Common questions
- Are there cancer clinical trials near Chicago?
- Yes. We're currently tracking 620 recruiting cancer studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.